

**Date: 08 August 2025**

**To**

The Secretary

**BSE Limited**

Phiroze Jeejeebhoy Towers

Dalal Street

Mumbai - 400 001

**Scrip Code: 544293**

The Secretary

**National Stock Exchange of India Limited**

Exchange Plaza, Plot No. C/1. G Block

Bandra -Kurla Complex, Bandra (East)

Mumbai- 400 051

**Scrip Symbol : SURAKSHA**

Dear Sir / Ma'am,

**Reg: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015**

**Sub: Press release in respect of unaudited (standalone and consolidated) financial results of the Company for quarter and three months ended 30 June 2025**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed herewith the press release in relation to the unaudited (standalone and consolidated) financial results of the Company for quarter and three months ended 30 June 2025.

Further, details as required to be disclosed as per BSE's Circular No. 20230714-34 dated 14 July 2023, and NSE's Circular No. NSE/CML/2023/57 dated 14 July 2023, are as under:

Date of occurrence of Event/Information: 08 August 2025

Time of occurrence of Event/Information: 6.26 pm (IST)

This may please be informed to all the concerned.

For **Suraksha Diagnostic Limited**

---

**Mamta Jain**

Company Secretary & Compliance Officer

**Encl:** As above

**Suraksha Diagnostic Limited**

**CIN:** L85110WB2005PLC102265

**Reg Office:** 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town  
Kolkata-700 156, West Bengal, India

**E-mail:** investors@surakshanet.com | **Website:** www.surakshanet.com

**Phone:** (033) 6605 9750





## Consistent Growth Delivers Strong Performance for Q1 FY26

**Total Income for Q1 FY26 increased by 18.83% year-on-year**

**Q1 FY26 EBITDA, grew by 13.51% year-on-year**

**Kolkata, 8<sup>th</sup> August 2025:** Suraksha Diagnostic Limited, the largest integrated diagnostic chain in East India, announced its unaudited financial results for the quarter ended 30<sup>th</sup> June 2025.

## Q1 FY26 Financial Performance Snapshot (Y-o-Y)

Total Income	EBITDA	Profit After Tax	EPS
₹ 734.92 million	₹ 246.56 million	₹ 91.75 million	₹ 1.80
 +18.83%	 +13.51%	 +19.67%	 ₹ 0.31

## Key Financial Highlights

Particulars	Q1 FY26	Q1 FY25	Y-o-Y	Q4 FY25	Q-o-Q
Total Income (₹ million)	734.92	618.48	18.83%	659.12	11.50%
EBTIDA (₹ million)	246.56	217.21	13.51%	200.05	23.25%
EBTIDA Margin (%)	33.97%	35.77%	-180 bps	30.73%	324 bps
PAT (₹ million)	91.75	76.67	19.7%	71.71	27.95%
PAT Margin (%)	12.64%	12.62%	2 bps	11.02%	162 bps

**Highlights:****Revenue from Operations:**

- For Q1 FY26, the company reported revenue from operations of ₹ 725.86 million, reflecting a growth of 19.52% compared to the same quarter last year.

**EBITDA:**

- EBITDA for Q1 FY26 reached ₹ 246.56 million, marking a 13.51% increase from Q1 FY25. The EBITDA margin for Q1 FY26 stood at 33.97%

**Profit After Tax (PAT):**

- PAT for Q1 FY26 stood at ₹ 91.75 million, reflecting a growth of 19.67% year-on-year. The PAT margin for Q1 FY26 was 12.64%

**Other Highlights:**

- Launched Suraksha Genomics, a dedicated vertical offering cutting-edge genetic and molecular testing services. This state-of-the-art facility brings comprehensive capabilities across key domains, including prenatal diagnostics (QF-PCR, Karyotyping, FISH, Microarray, and NIPT), identification of inherited disorders (such as single-gene mutation analysis and whole exome sequencing), pharmacogenomics, and specialized oncology panels.
- Acquired 63% stake in Fetomat Wellness Private Limited ('Fetomat') on 09<sup>th</sup> April 2025. Fetomat, a specialized healthcare provider focused on pregnancy care, women's ultrasound scanning, prenatal diagnostics, genetic counselling, and medical training for doctors, marks a strategic addition to our portfolio. We believe this acquisition creates strong synergies with our existing operations and unlocks new opportunities for sustainable growth in the healthcare segment.
- Expanded our footprint with addition of three new centres in the quarter, one each in small, medium and large format.

**Commenting on the results Ms Ritu Mittal, Joint Managing Director & CEO said, -**

"We are pleased to report a strong performance for Q1 FY26, driven by consistent growth across our operations. In the quarter we have also marked major milestone with the launch of Suraksha Genomics, this new vertical, equipped with state-of-the-art high-throughput sequencing platforms, positions us at the forefront of precision medicine in Eastern India.

Our strategic focus remains ambitious and future-ready. We are actively expanding into whole genome and metagenomic testing, while integrating AI-assisted variant interpretation to elevate diagnostic accuracy. Additionally, we are laying the groundwork for population-scale genomic screening programs, an initiative that holds transformative potential for public health. Clinical partnerships continue to be a cornerstone of our approach, enabling us to translate scientific advancements into meaningful improvements in patient care and research outcomes.

As newer centres stabilize and begin contributing significantly, we expect to see a stronger and more profitable financial profile across our network. We remain committed to innovation, operational excellence, and sustainable growth as we advance our mission to redefine healthcare delivery through genomics."

**About Suraksha Diagnostic Limited:**

Suraksha Diagnostic Limited is a leading provider of integrated solutions in pathology and radiology testing, as well as medical consultation services, offering a seamless experience to customers through an extensive operational network. The company is the largest integrated diagnostic chain with a presence in the states of West Bengal, Bihar, Assam and Meghalaya.

The company's central reference laboratory is accredited by the College of American Pathologists, while the 7 laboratories hold National Accreditation Board for Testing and Calibration Laboratories (NABL) accreditation, and the 3 advanced diagnostic centres are accredited by the National Accreditation Board for Hospitals & Healthcare Providers (NABH).



Company: Suraksha Diagnostic Limited	Investor Relations: Orient Capital
Email: <a href="mailto:investors@surakshanet.com">investors@surakshanet.com</a>	Name: Mr. Ashish Tendulkar Email: <a href="mailto:ashish.tendulkar@in.mpms.mufg.com">ashish.tendulkar@in.mpms.mufg.com</a>
CIN: L85110WB2005PLC102265	Name: Pooja Swami Email: <a href="mailto:pooja.swami@in.mpms.mufg.com">pooja.swami@in.mpms.mufg.com</a>
Website: <a href="https://www.surakshanet.com/">https://www.surakshanet.com/</a>	Meeting Request Link – <a href="#">Click Here</a>

### **Safe Harbor**

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. Past performance also should not be simply extrapolated into the future. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.